CA
CABA.US Cabaletta Bio Inc
- Market cap
- USD 276M
- P/E
- -
- P/B
- 1.01x
- ROE
- -69.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CABA.US undervalued?
Graham numberThe Graham number of Cabaletta Bio Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cabaletta Bio Inc fundamental analysis
No fundamental analysis for Cabaletta Bio Inc yet.
Cabaletta Bio Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, …
Full company profileCabaletta Bio Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cabaletta Bio Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -104K | 0.01 | -733K | -3.68M | -1.43M | -4.81M | -1.65M | - |
| Operating Income | -250K | -6.19M | -18.7M | -33.8M | -46.3M | -54.1M | -74.7M | -125M | -172M | -201M |
| EBITDA | 83.3K | -12.2M | -18.6M | -33.5M | -45.6M | -53.0M | -66.2M | -113M | -164M | -193M |
| Net Income | -250K | -12.2M | -15.1M | -32.5M | -45.5M | -51.8M | -67.7M | -116M | -168M | -197M |
| EPS | -0.01 | -0.84 | -2.76 | -1.40 | -1.77 | -1.77 | -1.65 | -2.34 | -1.64 | -1.05 |
| Balance Sheet | ||||||||||
| Total Assets | 1.00K | 34.2M | 141M | 115M | 126M | 117M | 254M | 185M | 165M | 336M |
| Total Liabilities | 250K | 44.9M | 3.15M | 5.18M | 8.38M | 12.4M | 17.5M | 32.7M | 53.0M | 52.6M |
| Shareholders' Equity | -249K | -10.7M | 138M | 110M | 118M | 105M | 236M | 152M | 112M | 284M |
| Cash & Short-term Investments | 1.00K | 33.0M | 136M | 109M | 122M | 107M | 241M | 164M | 134M | 299M |
| Total Debt | - | 43.9M | - | - | - | 5.14M | 5.02M | 15.6M | 27.1M | 23.2M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.66M | -4.66M | -16.0M | -26.8M | -34.1M | -46.4M | -53.5M | -88.2M | -131M | -169M |
| Capital Expenditure | 693K | 693K | 693K | 635K | 1.17M | 2.45M | 687K | 2.21M | 1.23M | 189K |
| Free Cash Flow | - | -4.66M | -16.7M | -27.4M | -35.3M | -48.8M | -54.2M | -90.4M | -132M | -169M |
| Ratios | ||||||||||
| ROE | - | - | -10.9% | -29.7% | -38.6% | -49.6% | -28.7% | -76.1% | -149.8% | -69.3% |
| ROA | -25,000.0% | -35.7% | -10.7% | -28.3% | -36.0% | -44.3% | -26.7% | -62.6% | -101.7% | -58.5% |
| Net Profit Margin | - | - | - | -324,910,000,000.0% | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | - | 0.05x | 0.02x | 0.10x | 0.24x | 0.08x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cabaletta Bio Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 10.1M | 1.84 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cabaletta Bio Inc
- Insiders 0.76%
- Institutions 83.16%
- Public & others 16.09%
- Shares outstanding 216M
- Free float 197M
Top funds holding CABA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Value | 8.40M | 3.89% | +9.96% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 7.10M | 3.29% | +43.12% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 5.31M | 2.46% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 5.22M | 2.42% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 4.11M | 1.90% | 0.00% | Oct 2026 |
| T. Rowe Price Health Sciences | 3.35M | 1.55% | -4.07% | Sep 2026 |
| PGIM Jennison Small Company A | 2.70M | 1.25% | 0.00% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 1.82M | 0.84% | +0.27% | Oct 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.54M | 0.71% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 1.24M | 0.58% | +1.21% | Aug 2026 |
| iShares Biotechnology ETF | 1.14M | 0.53% | -0.19% | Oct 2026 |
| T. Rowe Price New Horizons | 1.11M | 0.51% | -11.03% | Sep 2026 |
| Vanguard Russell 2000 ETF | 960K | 0.44% | +48.26% | Sep 2026 |
| Franklin Biotechnology Discovery A | 877K | 0.41% | 0.00% | Sep 2026 |
| International Biotechnology Ord | 857K | 0.40% | 0.00% | Jul 2026 |
| iShares Russell 2000 Growth ETF | 784K | 0.36% | -0.38% | Oct 2026 |
| Fidelity Extended Market Index | 749K | 0.35% | -8.41% | Sep 2026 |
| iShares Russell 2000 Value ETF | 746K | 0.35% | 0.00% | Oct 2026 |
| T. Rowe Price Small-Cap Stock | 729K | 0.34% | -47.37% | Sep 2026 |
| Simplify Propel Opportunities ETF | 556K | 0.26% | 0.00% | Oct 2026 |
Top institutions holding CABA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jennison Associates LLC | 20.0M | 9.29% | +123.33% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 18.9M | 8.75% | +70.31% | Jun 2026 |
| Bain Capital Life Sciences Investors, LLC | 17.2M | 7.99% | +78.17% | Jun 2026 |
| BlackRock Inc | 10.8M | 4.99% | +353.21% | Jun 2026 |
| Adage Capital Partners Gp LLC | 9.17M | 4.25% | +3.91% | Jun 2026 |
| State Street Corp | 7.84M | 3.63% | +1,568.02% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.23M | 3.35% | +79.38% | Jun 2026 |
| Cormorant Asset Management, LLC | 5.00M | 2.32% | -9.09% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 4.42M | 2.05% | +899.07% | Jun 2026 |
| Woodline Partners LP | 4.20M | 1.95% | +235.95% | Jun 2026 |
| NORGES BANK | 4.11M | 1.91% | 0.00% | Jun 2026 |
| Opaleye Management Inc | 3.86M | 1.79% | +179.99% | Jun 2026 |
| Citadel Advisors Llc | 3.52M | 1.63% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 3.46M | 1.60% | +205.27% | Jun 2026 |
| Franklin Templeton Inc | 2.41M | 1.12% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.21M | 1.03% | +182.40% | Jun 2026 |
| Millennium Management LLC | 2.07M | 0.96% | -64.96% | Jun 2026 |
| CANTOR FITZGERALD, L. P. | 1.60M | 0.74% | +109.15% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.57M | 0.73% | -28.16% | Jun 2026 |
| Renaissance Technologies Corp | 1.54M | 0.71% | -24.62% | Jun 2026 |
Cabaletta Bio Inc company profile
- Company name
- Cabaletta Bio Inc
- Ticker
- CABA.US
- Exchange
- USA Stocks
- Listed since
- Oct 25, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 154
- Fiscal year end
- December
- Address
- 2929 Arch Street, Philadelphia, PA, United States, 19104
- Phone
- 267 759 3100
- Website
- cabalettabio.com
About Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, a CAAR T cell therapy that is in Phase 1 clinical trial for the treatment of mucosal PV; and MuSK-CAART, an investigational cell therapy in Phase 1 trial for treating patients with anti-muscle-specific kinase (MuSK) antibody positive myasthenia gravis. It has collaborations with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; Autolus Holdings (UK) Limited; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Cabaletta Bio Inc management
10- Dr. Steven A. Nichtberger M.D.Co-Founder, Chairman, CEO & President · born 1961
- Dr. David J. Chang FACR, M.D., M.P.H.Chief Medical Officer · born 1963
- Dr. Gwendolyn K. Binder Ph.D.President of Science & Technology · born 1975
- Dr. Michael C. Milone M.D., Ph.D.Co-Founder & Co-Chair of Scientific Advisory Board
- Dr. Aimee Payne M.D., Ph.D.Co-Founder & Co-Chair of Scientific Advisory Board
- Mr. Anup Marda M.B.A.Chief Financial Officer · born 1978
- Dr. Qing Sarah Yuan Ph.D.Chief Technology Officer · born 1971
- Dr. Samik Basu M.D.Chief Scientific Officer
- Mr. Michael Gerard J.D.General Counsel & Secretary · born 1980
- Ms. Heather Harte-Hall M.Sc.Chief Compliance Officer